Targeted Radionuclide Therapy with A 177Lu-labeled Anti-HER2 Nanobody

Matthias D'huyvetter, Cécile Vincke, Catarina Xavier, An Aerts, Nathalie Impens, Sarah Baatout, Hendrik De Raeve, Serge Muyldermans, Vicky Caveliers, Nick Devoogdt, Tony Lahoutte

Research outputpeer-review


RIT (Radioimmunotherapy) has become an attractive strategy in cancer treatment, but still faces important drawbacks due to poor tumor penetration and undesirable pharmacokinetics of the targeting vehicles. Smaller radiolabeled antibody fragments and peptides feature highly specific target accumulation, resulting in low accumulation in healthy tissue, except for the kidneys. Nanobodies are the smallest (MW
Original languageEnglish
Pages (from-to)708-720
Issue number7
StatePublished - Apr 2014

Cite this